CollPlant Biotechnologies (CLGN) posted a second quarter net loss of $4.21 million or $0.37 per share compared to profit of $5.76 million or $0.49 per share, a year ago. Non-GAAP net loss was $3.8 million, or $0.33 per share, compared to net income of $6.0 million, or $0.53 basic per share, prior year.
Revenue was $249 thousand compared to $10.18 million. The company said the decrease in revenues is mainly related to the achievement of a milestone with respect to the AbbVie agreement, which triggered a $10 million payment in 2023.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.